RE:RE:RE:RE:Reimbursement Agreement in Italy for Trogarzo® You have heard of delayed release drugs, this PR looks like a delayed release PR. But maybe they had to wait for some official document before they could formally announce it.
In general in a bubble, the more PR's the better. You never know when one is going to get the stock price roaring, even if it does not make a lot of sense to people who are watching the stock closely.
All that being said, selling drugs in Europe can be a trying experience. The drug was approved there over two years ago and this appears to be the first formal re-imbursement deal with any of the governments. Such delays do not inspire someone from the US to desire a more socialized medical situation! Let's hope Trogarzo's competitors have an equally hard time getting official re-imbursement in place (I say official as a small number of patients in some European countries have already been able to access Trogarzo via other methods), but covid may not be the same impediment to them as it was to TH. Hopefully, TH can get a decent amount of patients on Trogarzo before the competitors arrive and then maintain most of those patients due to the unwillingness for an MDR patient and their doctor to give halt a treatment like Trogarzo that si working. In the US, it certainly appears that more than I would have thought have been willing to switch to pills.
I have been noticing TV commercials here in the US for Viiv's new once a month injection for first line HIV therapy. Perhaps if this proves successful, it will help on the margin for US Trogarzo sales as the whole HIV ecosystem gets more used to infrequent injections versus pills.
Bucknelly21 wrote: Sometimes I get confused on what they think is pr worthy... we already knew This, yet a very relevant paper will be released about their oncology or Nash pipeline and nothing... scarlet or jfm have to dig it up from some random website